Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated With Familial Adenomatous Polyposis
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Familial adenomatous polyposis
- Focus Adverse reactions; Therapeutic Use
- 29 Nov 2017 Status changed from not yet recruiting to recruiting.
- 26 Sep 2017 Planned End Date changed from 1 Jun 2019 to 1 Sep 2019.
- 26 Sep 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Sep 2019.